GlassScriptPhysician profile
Ronald D Massari
NPI 1073510640
$5,185.49
in general payments reported to CMS, 2019-2025
34 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $127 · 2021: $391 · 2022: $987 · 2023: $876 · 2024: $1,037 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,975.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $725.93 | 2019-2025 | |
| Pfizer INC. | $526.20 | 2019-2025 | |
| Amgen INC. | $451.78 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.23 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $338.47 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $327.82 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $314.14 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.96 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $199.03 | 2022-2024 | Optimizer, Optimizer |
| Sanofi-Aventis U.S. LLC | $163.14 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $159.89 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $137.21 | 2019-2023 | |
| Abbott Laboratories | $136.67 | 2023-2024 | Cardiomems |
| Esperion Therapeutics, INC. | $134.40 | 2021-2025 | Nexletol |
| Irhythm Technologies, INC. | $127.07 | 2019-2022 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Massari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.